Learn more

NORTH AMERICAN VACCINE INC

Overview
  • Total Patents
    87
About

NORTH AMERICAN VACCINE INC has a total of 87 patent applications. Its first patent ever was published in 1991. It filed its patents most often in Canada, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are CEL SCI CORP, MEGAN HEALTH INC and AVENTIS PASTEUR.

Patent filings per year

Chart showing NORTH AMERICAN VACCINE INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Michon Francis 45
#2 Tai Joseph Y 34
#3 Liang Shu-Mei 22
#4 Blake Milan S 19
#5 Penney Christopher L 18
#6 Pullen Jeffrey K 17
#7 Jennings Harold J 16
#8 Penny Christopher L 10
#9 Soper Thomas S 9
#10 Hronowski Lucjan J J 7

Latest patents

Publication Filing date Title
WO0010599A2 IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
CN1272062A Immunogenic conjugates comprising group meningococcal porin and an i (H. influenzae) polysaccharide
AU4330797A Non-IgA Fc binding forms of the group B streptococcal beta antigens
US5747287A Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
CA2244989A1 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines
AU2115897A Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines
US6284884B1 Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5866135A Group A streptococcal polysaccharide immunogenic compositions and methods
US6153406A Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5425946A Vaccines against group C Neisseria meningitidis
NZ239643A Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
IL97985D0 Improved vaccine compositions